Revista clinica espanola · 2025
Expert consensus on interstitial lung disease associated with systemic autoimmune diseases. Executive summary.
СтатьяConsensus StatementКлинические рекомендацииПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
González-García A, Akasbi M, Brito-Zerón M P, Callejas J L, Cusacovich I, Jiménez Segovia F, Martín Cascón M, Prieto-González S, Sáez Comet L, Simeón C P, Solans Laque R, García Morillo J S, Systemic Autoimmune Disease Group (GEAS) of the Spanish Society of Internal Medicine (SEMI)
Аннотация
Interstitial lung disease (ILD) is a frequent and potentially fatal manifestation of systemic autoimmune diseases (SAD). Early screening, diagnosis, and treatment with immunomodulators, and in some cases, antifibrotics, as well as appropriate follow-up, are essential to improving patients' quality of life and survival. The complexity of these diseases and the limited robust evidence to guide clinical decision-making lead to significant variability in management guidelines. In this article, a group of experts in SAD has developed recommendations for the screening, diagnosis, treatment, and follow-up of ILD, considering the latest evidence, their clinical experience, and the results of a survey conducted among specialists. The diseases included are systemic sclerosis, Sjögren's disease, idiopathic inflammatory myopathy, ANCA-associated vasculitis, sarcoidosis and systemic lupus erythematosus.